The far-reaching scope of neuroinflammation after traumatic brain injury

  • An Erratum to this article was published on 04 August 2017

Key Points

  • Traumatic brain injury (TBI) is an important public health issue: the global incidence of TBI is on the rise, and mild, repetitive and blast injuries, in particular, are increasingly recognized in the popular press

  • Neuroinflammation, triggered by release of endogenous danger signals and innate immune activation, is crucial to recovery after TBI; however, a dysregulated immune response can result in secondary injury

  • After TBI, the activity of microglia and infiltrating macrophages and adaptive immune cells is driven by extracellular injury signals and intracellular molecular pathways that might represent novel therapeutic targets

  • Trials assessing immunomodulatory interventions should account for changes in neuroinflammation that occur over time, between injury type and severity, and across patient characteristics such as age, sex and genetic variability

  • Some individuals with TBI develop chronic neuroinflammation, which can last for years after the injury, and is being investigated as a link to accelerated neurodegeneration and chronic traumatic encephalopathy

Abstract

The 'silent epidemic' of traumatic brain injury (TBI) has been placed in the spotlight as a result of clinical investigations and popular press coverage of athletes and veterans with single or repetitive head injuries. Neuroinflammation can cause acute secondary injury after TBI, and has been linked to chronic neurodegenerative diseases; however, anti-inflammatory agents have failed to improve TBI outcomes in clinical trials. In this Review, we therefore propose a new framework of targeted immunomodulation after TBI for future exploration. Our framework incorporates factors such as the time from injury, mechanism of injury, and secondary insults in considering potential treatment options. Structuring our discussion around the dynamics of the immune response to TBI — from initial triggers to chronic neuroinflammation — we consider the ability of soluble and cellular inflammatory mediators to promote repair and regeneration versus secondary injury and neurodegeneration. We summarize both animal model and human studies, with clinical data explicitly defined throughout this Review. Recent advances in neuroimmunology and TBI-responsive neuroinflammation are incorporated, including concepts of inflammasomes, mechanisms of microglial polarization, and glymphatic clearance. Moreover, we highlight findings that could offer novel therapeutic targets for translational and clinical research, assimilate evidence from other brain injury models, and identify outstanding questions in the field.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Neuroinflammation after traumatic brain injury.
Figure 2: Polarization of microglia and macrophages following TBI.
Figure 3: Novel TBI therapies targeting inflammation at different time points.
Figure 4: Effects of chronic neuroinflammation.

Change history

  • 04 August 2017

    In the initially published version of this article, reference 194 was incorrectly cited as reference 193 in the Conclusions section. This error has been corrected in the HTML and PDF versions of the article.

References

  1. 1

    Roozenbeek, B., Maas, A. I. & Menon, D. K. Changing patterns in the epidemiology of traumatic brain injury. Nat. Rev. Neurol. 9, 231–236 (2013).

  2. 2

    Feigin, V. L. et al. Incidence of traumatic brain injury in New Zealand: a population-based study. Lancet Neurol. 12, 53–64 (2013).

  3. 3

    Goldstein, L. E. et al. Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model. Sci. Transl Med. 4, 134ra60 (2012).

  4. 4

    Corps, K. N., Roth, T. L. & McGavern, D. B. Inflammation and neuroprotection in traumatic brain injury. JAMA Neurol. 72, 355–362 (2015).

  5. 5

    Csuka, E. et al. IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: relationship to IL-6, TNF-α, TGF-β1 and blood–brain barrier function. J. Neuroimmunol. 101, 211–221 (1999).

  6. 6

    Frugier, T., Morganti-Kossmann, M. C., O'Reilly, D. & McLean, C. A. In situ detection of inflammatory mediators in post mortem human brain tissue after traumatic injury. J. Neurotrauma 27, 497–507 (2010).

  7. 7

    Kossmann, T. et al. Interleukin-8 released into the cerebrospinal fluid after brain injury is associated with blood–brain barrier dysfunction and nerve growth factor production. J. Cereb. Blood Flow Metab. 17, 280–289 (1997).

  8. 8

    Semple, B. D., Kossmann, T. & Morganti-Kossmann, M. C. Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. J. Cereb. Blood Flow Metab. 30, 459–473 (2010). Excellent review on the several crucial roles of chemokines and their receptors in response to traumatic brain injury, with a focus on two of the best-studied chemokines, CCL2 and CXCL8.

  9. 9

    Ziebell, J. M. & Morganti-Kossmann, M. C. Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. Neurotherapeutics 7, 22–30 (2010).

  10. 10

    Roberts, I. et al. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet 364, 1321–1328 (2004).

  11. 11

    Hutchison, J. S. et al. Hypothermia therapy after traumatic brain injury in children. N. Engl. J. Med. 358, 2447–2456 (2008).

  12. 12

    Xiong, Y., Mahmood, A. & Chopp, M. Animal models of traumatic brain injury. Nat. Rev. Neurosci. 14, 128–142 (2013).

  13. 13

    Marklund, N. & Hillered, L. Animal modelling of traumatic brain injury in preclinical drug development: where do we go from here? Br. J. Pharmacol. 164, 1207–1229 (2011).

  14. 14

    Sheikh, A. M. et al. Lysophosphatidylcholine induces glial cell activation: role of rho kinase. Glia 57, 898–907 (2009).

  15. 15

    Uchida, K. Redox-derived damage-associated molecular patterns: ligand function of lipid peroxidation adducts. Redox Biol. 1, 94–96 (2013).

  16. 16

    Ransohoff, R. M. & Brown, M. A. Innate immunity in the central nervous system. J. Clin. Invest. 122, 1164–1171 (2012).

  17. 17

    Scherbel, U. et al. Differential acute and chronic responses of tumor necrosis factor-deficient mice to experimental brain injury. Proc. Natl Acad. Sci. USA 96, 8721–8726 (1999).

  18. 18

    Sinz, E. H. et al. Inducible nitric oxide synthase is an endogenous neuroprotectant after traumatic brain injury in rats and mice. J. Clin. Invest. 104, 647–656 (1999).

  19. 19

    You, Z. et al. Necrostatin-1 reduces histopathology and improves functional outcome after controlled cortical impact in mice. J. Cereb. Blood Flow Metab. 28, 1564–1573 (2008).

  20. 20

    Laird, M. D. et al. High mobility group box protein-1 promotes cerebral edema after traumatic brain injury via activation of toll-like receptor 4. Glia 62, 26–38 (2014).

  21. 21

    Au, A. K. et al. Cerebrospinal fluid levels of high-mobility group box 1 and cytochrome C predict outcome after pediatric traumatic brain injury. J. Neurotrauma 29, 2013–2021 (2012).

  22. 22

    Frank, M. G., Weber, M. D., Watkins, L. R. & Maier, S. F. Stress sounds the alarmin: the role of the danger-associated molecular pattern HMGB1 in stress-induced neuroinflammatory priming. Brain Behav. Immun. 48, 1–7 (2015).

  23. 23

    Martinon, F., Burns, K. & Tschopp, J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Mol. Cell 10, 417–426 (2002).

  24. 24

    de Rivero Vaccari, J. P. et al. Therapeutic neutralization of the NLRP1 inflammasome reduces the innate immune response and improves histopathology after traumatic brain injury. J. Cereb. Blood Flow Metab. 29, 1251–1261 (2009).

  25. 25

    Adamczak, S. E. et al. Pyroptotic neuronal cell death mediated by the AIM2 inflammasome. J. Cereb. Blood Flow Metab. 34, 621–629 (2014).

  26. 26

    Halle, A. et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nat. Immunol. 9, 857–865 (2008).

  27. 27

    Liu, H. D. et al. Expression of the NLRP3 inflammasome in cerebral cortex after traumatic brain injury in a rat model. Neurochem. Res. 38, 2072–2083 (2013).

  28. 28

    de Rivero Vaccari, J. P., Lotocki, G., Marcillo, A. E., Dietrich, W. D. & Keane, R. W. A molecular platform in neurons regulates inflammation after spinal cord injury. J. Neurosci. 28, 3404–3414 (2008).

  29. 29

    Lukens, J. R., Barr, M. J., Chaplin, D. D., Chi, H. & Kanneganti, T. D. Inflammasome-derived IL-1β regulates the production of GM-CSF by CD4+ T cells and γδ T cells. J. Immunol. 188, 3107–3115 (2012).

  30. 30

    Meissner, F., Molawi, K. & Zychlinsky, A. Mutant superoxide dismutase 1-induced IL-1β accelerates ALS pathogenesis. Proc. Natl Acad. Sci. USA 107, 13046–13050 (2010).

  31. 31

    Palmer, A. M., Marion, D. W., Botscheller, M. L., Bowen, D. M. & DeKosky, S. T. Increased transmitter amino acid concentration in human ventricular CSF after brain trauma. Neuroreport 6, 153–156 (1994).

  32. 32

    Ruppel, R. A. et al. Excitatory amino acid concentrations in ventricular cerebrospinal fluid after severe traumatic brain injury in infants and children: the role of child abuse. J. Pediatr. 138, 18–25 (2001).

  33. 33

    Kochanek, P. M. et al. Biochemical, cellular, and molecular mechanisms in the evolution of secondary damage after severe traumatic brain injury in infants and children: lessons learned from the bedside. Pediatr. Crit. Care Med. 1, 4–19 (2000).

  34. 34

    Viviani, B., Boraso, M., Marchetti, N. & Marinovich, M. Perspectives on neuroinflammation and excitotoxicity: a neurotoxic conspiracy? Neurotoxicology 43, 10–20 (2014).

  35. 35

    Ikonomidou, C. & Turski, L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol. 1, 383–386 (2002).

  36. 36

    Verrier, J. D. et al. Expression of the 2′,3′-cAMP-adenosine pathway in astrocytes and microglia. J. Neurochem. 118, 979–987 (2011).

  37. 37

    Kochanek, P. M. et al. Adenosine A1 receptor knockout mice develop lethal status epilepticus after experimental traumatic brain injury. J. Cereb. Blood Flow Metab. 26, 565–575 (2006).

  38. 38

    Haselkorn, M. L. et al. Adenosine A1 receptor activation as a brake on the microglial response after experimental traumatic brain injury in mice. J. Neurotrauma 27, 901–910 (2010).

  39. 39

    Jackson, E. K., Boison, D., Schwarzschild, M. A. & Kochanek, P. M. Purines: forgotten mediators in traumatic brain injury. J. Neurochem. 137, 142–153 (2016).

  40. 40

    Suliman, H. B. & Piantadosi, C. A. Mitochondrial quality control as a therapeutic target. Pharmacol. Rev. 68, 20–48 (2016).

  41. 41

    Chu, C. T., Ji, J. & Dagda, R. K. Cardiolipin externalization to the outer mitochondrial membrane acts as an elimination signal for mitophagy in neuronal cells. Nat. Cell Biol. 15, 1197–1205 (2013).

  42. 42

    Iyer, S. S. et al. Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation. Immunity 39, 311–323 (2013).

  43. 43

    Walko, T. D. III et al. Cerebrospinal fluid mitochondrial DNA: a novel DAMP in pediatric traumatic brain injury. Shock 41, 499–503 (2014).

  44. 44

    Galluzzi, L., Kepp, O. & Kroemer, G. Mitochondria: master regulators of danger signalling. Nat. Rev. Mol. Cell Biol. 13, 780–788 (2012).

  45. 45

    Balasubramanian, K. et al. Dichotomous roles for externalized cardiolipin in extracellular signaling: promotion of phagocytosis and attenuation of innate immunity. Sci. Signal. 8, ra95 (2015).

  46. 46

    Fang, H. et al. CD36-mediated hematoma absorption following intracerebral hemorrhage: negative regulation by TLR4 signaling. J. Immunol. 192, 5984–5992 (2014).

  47. 47

    Wagner, K. R., Sharp, F. R., Ardizzone, T. D., Lu, A. & Clark, J. F. Heme and iron metabolism: role in cerebral hemorrhage. J. Cereb. Blood Flow Metab. 23, 629–652 (2003).

  48. 48

    Bellander, B. M., Singhrao, S. K., Ohlsson, M., Mattsson, P. & Svensson, M. Complement activation in the human brain after traumatic head injury. J. Neurotrauma 18, 1295–1311 (2001).

  49. 49

    Stahel, P. F. et al. Intrathecal levels of complement-derived soluble membrane attack complex (sC5b-9) correlate with blood–brain barrier dysfunction in patients with traumatic brain injury. J. Neurotrauma 18, 773–781 (2001).

  50. 50

    Stahel, P. F. et al. Absence of the complement regulatory molecule CD59a leads to exacerbated neuropathology after traumatic brain injury in mice. J. Neuroinflammation 6, 2 (2009).

  51. 51

    Brennan, F. H., Anderson, A. J., Taylor, S. M., Woodruff, T. M. & Ruitenberg, M. J. Complement activation in the injured central nervous system: another dual-edged sword? J. Neuroinflammation 9, 137 (2012). Review of complement activation and dysregulation after brain and spinal cord injury, including several complement-targeted therapeutics.

  52. 52

    Rich, M. C. et al. Site-targeted complement inhibition by a complement receptor 2-conjugated inhibitor (mTT30) ameliorates post-injury neuropathology in mouse brains. Neurosci. Lett. 617, 188–194 (2016).

  53. 53

    Ruseva, M. M., Ramaglia, V., Morgan, B. P. & Harris, C. L. An anticomplement agent that homes to the damaged brain and promotes recovery after traumatic brain injury in mice. Proc. Natl Acad. Sci. USA 112, 14319–14324 (2015).

  54. 54

    Zhang, Z., Zhang, Z. Y., Wu, Y. & Schluesener, H. J. Lesional accumulation of CD163+ macrophages/microglia in rat traumatic brain injury. Brain Res. 1461, 102–110 (2012).

  55. 55

    Wang, X., Mori, T., Sumii, T. & Lo, E. H. Hemoglobin-induced cytotoxicity in rat cerebral cortical neurons: caspase activation and oxidative stress. Stroke 33, 1882–1888 (2002).

  56. 56

    Willmore, L. J. & Ueda, Y. Posttraumatic epilepsy: hemorrhage, free radicals and the molecular regulation of glutamate. Neurochem. Res. 34, 688–697 (2009).

  57. 57

    Newell, E. et al. Cerebrospinal fluid markers of macrophage and lymphocyte activation after traumatic brain injury in children. Pediatr. Crit. Care Med. 16, 549–557 (2015).

  58. 58

    Kochanek, P. M. et al. Screening of biochemical and molecular mechanisms of secondary injury and repair in the brain after experimental blast-induced traumatic brain injury in rats. J. Neurotrauma 30, 920–937 (2013).

  59. 59

    Bandak, F. A., Ling, G., Bandak, A. & De Lanerolle, N. C. Injury biomechanics, neuropathology, and simplified physics of explosive blast and impact mild traumatic brain injury. Handb. Clin. Neurol. 127, 89–104 (2015).

  60. 60

    Kovesdi, E. et al. Acute minocycline treatment mitigates the symptoms of mild blast-induced traumatic brain injury. Front. Neurol. 3, 111 (2012).

  61. 61

    Clark, R. S., Schiding, J. K., Kaczorowski, S. L., Marion, D. W. & Kochanek, P. M. Neutrophil accumulation after traumatic brain injury in rats: comparison of weight drop and controlled cortical impact models. J. Neurotrauma 11, 499–506 (1994).

  62. 62

    Carlos, T. M., Clark, R. S., Franicola-Higgins, D., Schiding, J. K. & Kochanek, P. M. Expression of endothelial adhesion molecules and recruitment of neutrophils after traumatic brain injury in rats. J. Leukoc. Biol. 61, 279–285 (1997).

  63. 63

    Bao, F. et al. A CD11d monoclonal antibody treatment reduces tissue injury and improves neurological outcome after fluid percussion brain injury in rats. J. Neurotrauma 29, 2375–2392 (2012).

  64. 64

    Weaver, L. C. et al. CD11d integrin blockade reduces the systemic inflammatory response syndrome after traumatic brain injury in rats. Exp. Neurol. 271, 409–422 (2015).

  65. 65

    Auffray, C. et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 317, 666–670 (2007).

  66. 66

    Hsieh, C. L. et al. Traumatic brain injury induces macrophage subsets in the brain. Eur. J. Immunol. 43, 2010–2022 (2013).

  67. 67

    Morganti, J. M. et al. CCR2 antagonism alters brain macrophage polarization and ameliorates cognitive dysfunction induced by traumatic brain injury. J. Neurosci. 35, 748–760 (2015).

  68. 68

    Jin, X., Ishii, H., Bai, Z., Itokazu, T. & Yamashita, T. Temporal changes in cell marker expression and cellular infiltration in a controlled cortical impact model in adult male C57BL/6 mice. PLoS ONE 7, e41892 (2012).

  69. 69

    de Lanerolle, N. C., Lee, T. S. & Spencer, D. D. Astrocytes and epilepsy. Neurotherapeutics 7, 424–438 (2010).

  70. 70

    Burda, J. E., Bernstein, A. M. & Sofroniew, M. V. Astrocyte roles in traumatic brain injury. Exp. Neurol. 275, 305–315 (2016). Excellent review of astrocyte function in health and after traumatic brain injury, including proinflammatory and anti-inflammatory roles and importance in repair and regeneration.

  71. 71

    Turtzo, L. C. et al. Macrophagic and microglial responses after focal traumatic brain injury in the female rat. J. Neuroinflammation 11, 82 (2014).

  72. 72

    Loane, D. J. & Byrnes, K. R. Role of microglia in neurotrauma. Neurotherapeutics 7, 366–377 (2010).

  73. 73

    Morganti-Kossmann, M. C., Rancan, M., Stahel, P. F. & Kossmann, T. Inflammatory response in acute traumatic brain injury: a double-edged sword. Curr. Opin. Crit. Care 8, 101–105 (2002).

  74. 74

    David, S. & Kroner, A. Repertoire of microglial and macrophage responses after spinal cord injury. Nat. Rev. Neurosci. 12, 388–399 (2011).

  75. 75

    Kumar, A. & Loane, D. J. Neuroinflammation after traumatic brain injury: opportunities for therapeutic intervention. Brain Behav. Immun. 26, 1191–1201 (2012).

  76. 76

    Colton, C. A. Heterogeneity of microglial activation in the innate immune response in the brain. J. Neuroimmune Pharmacol. 4, 399–418 (2009).

  77. 77

    Sica, A. & Mantovani, A. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 122, 787–795 (2012).

  78. 78

    Loane, D. J., Kumar, A., Stoica, B. A., Cabatbat, R. & Faden, A. I. Progressive neurodegeneration after experimental brain trauma: association with chronic microglial activation. J. Neuropathol. Exp. Neurol. 73, 14–29 (2014).

  79. 79

    Wang, G. et al. Microglia/macrophage polarization dynamics in white matter after traumatic brain injury. J. Cereb. Blood Flow Metab. 33, 1864–1874 (2013).

  80. 80

    Loane, D. J. & Kumar, A. Microglia in the TBI brain: the good, the bad, and the dysregulated. Exp. Neurol. 275, 316–327 (2016).

  81. 81

    Fenn, A. M. et al. Immune activation promotes depression 1 month after diffuse brain injury: a role for primed microglia. Biol. Psychiatry 76, 575–584 (2014).

  82. 82

    Fenn, A. M. et al. Methylene blue attenuates traumatic brain injury-associated neuroinflammation and acute depressive-like behavior in mice. J. Neurotrauma 32, 127–138 (2015).

  83. 83

    Lee, K. D. et al. FTY720 reduces inflammation and promotes functional recovery after spinal cord injury. J. Neurotrauma 26, 2335–2344 (2009).

  84. 84

    Zhang, J., Zhang, A., Sun, Y., Cao, X. & Zhang, N. Treatment with immunosuppressants FTY720 and tacrolimus promotes functional recovery after spinal cord injury in rats. Tohoku J. Exp. Med. 219, 295–302 (2009).

  85. 85

    Norimatsu, Y. et al. FTY720 improves functional recovery after spinal cord injury by primarily nonimmunomodulatory mechanisms. Am. J. Pathol. 180, 1625–1635 (2012).

  86. 86

    Walsh, J. T. et al. MHCII-independent CD4+ T cells protect injured CNS neurons via IL-4. J. Clin. Invest. 125, 699–714 (2015).

  87. 87

    Kipnis, J. et al. Neuroprotective autoimmunity: naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system. Proc. Natl Acad. Sci. USA 99, 15620–15625 (2002).

  88. 88

    Yoles, E. et al. Protective autoimmunity is a physiological response to CNS trauma. J. Neurosci. 21, 3740–3748 (2001).

  89. 89

    Hammarberg, H. et al. Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. J. Neurosci. 20, 5283–5291 (2000).

  90. 90

    Linker, R., Gold, R. & Luhder, F. Function of neurotrophic factors beyond the nervous system: inflammation and autoimmune demyelination. Crit. Rev. Immunol. 29, 43–68 (2009).

  91. 91

    Filiano, A. J., Gadani, S. P. & Kipnis, J. Interactions of innate and adaptive immunity in brain development and function. Brain Res. 1617, 18–27 (2015).

  92. 92

    Gadani, S. P., Walsh, J. T., Smirnov, I., Zheng, J. & Kipnis, J. The glia-derived alarmin IL-33 orchestrates the immune response and promotes recovery following CNS injury. Neuron 85, 703–709 (2015).

  93. 93

    Lohning, M. et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc. Natl Acad. Sci. USA 95, 6930–6935 (1998).

  94. 94

    Burzyn, D. et al. A special population of regulatory T cells potentiates muscle repair. Cell 155, 1282–1295 (2013).

  95. 95

    Kuswanto, W. et al. Poor repair of skeletal muscle in aging mice reflects a defect in local, interleukin-33-dependent accumulation of regulatory T cells. Immunity 44, 355–367 (2016).

  96. 96

    Schiering, C. et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 513, 564–568 (2014).

  97. 97

    Fletcher, J. M., Lalor, S. J., Sweeney, C. M., Tubridy, N. & Mills, K. H. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin. Exp. Immunol. 162, 1–11 (2010).

  98. 98

    Patel, D. D. & Kuchroo, V. K. Th17 cell pathway in human immunity: lessons from genetics and therapeutic interventions. Immunity 43, 1040–1051 (2015).

  99. 99

    Shichita, T. et al. Pivotal role of cerebral interleukin-17-producing γδT cells in the delayed phase of ischemic brain injury. Nat. Med. 15, 946–950 (2009).

  100. 100

    Benakis, C. et al. Commensal microbiota affects ischemic stroke outcome by regulating intestinal γδ T cells. Nat. Med. 22, 516–523 (2016).

  101. 101

    Belkaid, Y. & Hand, T. W. Role of the microbiota in immunity and inflammation. Cell 157, 121–141 (2014).

  102. 102

    Kasper, L. H. The evolving role of the gut microbiome in human disease. FEBS Lett. 588, 4101 (2014).

  103. 103

    Cryan, J. F. & Dinan, T. G. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat. Rev. Neurosci. 13, 701–712 (2012).

  104. 104

    Kelly, J. R. et al. Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders. Front. Cell. Neurosci. 9, 392 (2015).

  105. 105

    Iliff, J. J. et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci. Transl Med. 4, 147ra111 (2012).

  106. 106

    Lee, H. et al. The effect of body posture on brain glymphatic transport. J. Neurosci. 35, 11034–11044 (2015).

  107. 107

    Xie, L. et al. Sleep drives metabolite clearance from the adult brain. Science 342, 373–377 (2013).

  108. 108

    Aspelund, A. et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J. Exp. Med. 212, 991–999 (2015).

  109. 109

    Louveau, A. et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337–341 (2015).

  110. 110

    Plog, B. A. et al. Biomarkers of traumatic injury are transported from brain to blood via the glymphatic system. J. Neurosci. 35, 518–526 (2015).

  111. 111

    Iliff, J. J., Chen, M. J., Plog, B. A., Zeppenfeld, D. M. & Soltero, M. Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. J. Neurosci. 34, 16180–16193 (2014).

  112. 112

    Tortella, F. C. & Leung, L. Y. Traumatic brain injury and polytrauma in theaters of combat: the case for neurotrauma resuscitation? Shock 44 (Suppl. 1), 17–26 (2015).

  113. 113

    Chesnut, R. M. et al. The role of secondary brain injury in determining outcome from severe head injury. J. Trauma 34, 216–222 (1993).

  114. 114

    Tisherman, S. A. et al. Detailed description of all deaths in both the shock and traumatic brain injury hypertonic saline trials of the Resuscitation Outcomes Consortium. Ann. Surg. 261, 586–590 (2015).

  115. 115

    Shein, S. et al. Hemorrhagic shock shifts the serum cytokine profile from pro-to anti-inflammatory after experimental traumatic brain injury in mice. J. Neurotrauma 31, 1386–1395 (2014).

  116. 116

    Hemerka, J. N. et al. Severe brief pressure-controlled hemorrhagic shock after traumatic brain injury exacerbates functional deficits and long-term neuropathological damage in mice. J. Neurotrauma 29, 2192–2208 (2012).

  117. 117

    Shiozaki, T. et al. Cerebrospinal fluid concentrations of anti-inflammatory mediators in early-phase severe traumatic brain injury. Shock 23, 406–410 (2005).

  118. 118

    Kumar, R. G. et al. Acute CSF interleukin-6 trajectories after TBI: associations with neuroinflammation, polytrauma, and outcome. Brain Behav. Immun. 45, 253–262 (2015).

  119. 119

    Simon, D. W., Vagni, V. M., Kochanek, P. M. & Clark, R. S. Combined neurotrauma models: experimental models combining traumatic brain injury and secondary insults. Methods Mol. Biol. 1462, 393–411 (2016).

  120. 120

    McDonald, S. J., Sun, M., Agoston, D. V. & Shultz, S. R. The effect of concomitant peripheral injury on traumatic brain injury pathobiology and outcome. J. Neuroinflammation 13, 90 (2016).

  121. 121

    Shultz, S. R. et al. Tibial fracture exacerbates traumatic brain injury outcomes and neuroinflammation in a novel mouse model of multitrauma. J. Cereb. Blood Flow Metab. 35, 1339–1347 (2015).

  122. 122

    Utagawa, A., Truettner, J. S., Dietrich, W. D. & Bramlett, H. M. Systemic inflammation exacerbates behavioral and histopathological consequences of isolated traumatic brain injury in rats. Exp. Neurol. 211, 283–291 (2008).

  123. 123

    Hang, C. H. et al. Effect of systemic LPS injection on cortical NF-κB activity and inflammatory response following traumatic brain injury in rats. Brain Res. 1026, 23–32 (2004).

  124. 124

    Titus, D. J., Furones, C., Atkins, C. M. & Dietrich, W. D. Emergence of cognitive deficits after mild traumatic brain injury due to hyperthermia. Exp. Neurol. 263, 254–262 (2015).

  125. 125

    Richardson, R. M., Sun, D. & Bullock, M. R. Neurogenesis after traumatic brain injury. Neurosurg. Clin. N. Am. 18, 169–181 (2007).

  126. 126

    Ekdahl, C. T., Claasen, J. H., Bonde, S., Kokaia, Z. & Lindvall, O. Inflammation is detrimental for neurogenesis in adult brain. Proc. Natl Acad. Sci. USA 100, 13632–13637 (2003).

  127. 127

    Whitney, N. P., Eidem, T. M., Peng, H., Huang, Y. & Zheng, J. C. Inflammation mediates varying effects in neurogenesis: relevance to the pathogenesis of brain injury and neurodegenerative disorders. J. Neurochem. 108, 1343–1359 (2009).

  128. 128

    Monje, M. L., Toda, H. & Palmer, T. D. Inflammatory blockade restores adult hippocampal neurogenesis. Science 302, 1760–1765 (2003).

  129. 129

    Butovsky, O. et al. Microglia activated by IL-4 or IFN-γ differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells. Mol. Cell. Neurosci. 31, 149–160 (2006).

  130. 130

    Piao, C. S. et al. Late exercise reduces neuroinflammation and cognitive dysfunction after traumatic brain injury. Neurobiol. Dis. 54, 252–263 (2013).

  131. 131

    Wang, B. & Jin, K. Current perspectives on the link between neuroinflammation and neurogenesis. Metab. Brain Dis. 30, 355–365 (2015).

  132. 132

    Bendlin, B. B. et al. Longitudinal changes in patients with traumatic brain injury assessed with diffusion-tensor and volumetric imaging. Neuroimage 42, 503–514 (2008).

  133. 133

    Trivedi, M. A. et al. Longitudinal changes in global brain volume between 79 and 409 days after traumatic brain injury: relationship with duration of coma. J. Neurotrauma 24, 766–771 (2007).

  134. 134

    Shaklai, S., Peretz, R., Spasser, R., Simantov, M. & Groswasser, Z. Long-term functional outcome after moderate-to-severe paediatric traumatic brain injury. Brain Inj. 28, 915–921 (2014).

  135. 135

    Ziebell, J. M., Adelson, P. D. & Lifshitz, J. Microglia: dismantling and rebuilding circuits after acute neurological injury. Metab. Brain Dis. 30, 393–400 (2015).

  136. 136

    Bellinger, F. P., Madamba, S. G., Campbell, I. L. & Siggins, G. R. Reduced long-term potentiation in the dentate gyrus of transgenic mice with cerebral overexpression of interleukin-6. Neurosci. Lett. 198, 95–98 (1995).

  137. 137

    Balschun, D. et al. Interleukin-6: a cytokine to forget. FASEB J. 18, 1788–1790 (2004).

  138. 138

    Boato, F. et al. Interleukin-1 beta and neurotrophin-3 synergistically promote neurite growth in vitro. J. Neuroinflammation 8, 183 (2011).

  139. 139

    Aungst, S. L., Kabadi, S. V., Thompson, S. M., Stoica, B. A. & Faden, A. I. Repeated mild traumatic brain injury causes chronic neuroinflammation, changes in hippocampal synaptic plasticity, and associated cognitive deficits. J. Cereb. Blood Flow Metab. 34, 1223–1232 (2014).

  140. 140

    Miron, V. E. et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat. Neurosci. 16, 1211–1218 (2013).

  141. 141

    Thau-Zuchman, O., Shohami, E., Alexandrovich, A. G. & Leker, R. R. Combination of vascular endothelial and fibroblast growth factor 2 for induction of neurogenesis and angiogenesis after traumatic brain injury. J. Mol. Neurosci. 47, 166–172 (2012).

  142. 142

    Saul, T. G., Ducker, T. B., Salcman, M. & Carro, E. Steroids in severe head injury: a prospective randomized clinical trial. J. Neurosurg. 54, 596–600 (1981).

  143. 143

    Braakman, R., Schouten, H. J., Blaauw-van Dishoeck, M. & Minderhoud, J. M. Megadose steroids in severe head injury. Results of a prospective double-blind clinical trial. J. Neurosurg. 58, 326–330 (1983).

  144. 144

    Gaab, M. R. et al. “Ultrahigh” dexamethasone in acute brain injury. Results from a prospective randomized double-blind multicenter trial (GUDHIS). German Ultrahigh Dexamethasone Head Injury Study Group. Zentralbl. Neurochir. 55, 135–143 (1994).

  145. 145

    Marshall, L. F. et al. A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury. J. Neurosurg. 89, 519–525 (1998).

  146. 146

    Asehnoune, K. et al. Hydrocortisone and fludrocortisone for prevention of hospital-acquired pneumonia in patients with severe traumatic brain injury (Corti-TC): a double-blind, multicentre phase 3, randomised placebo-controlled trial. Lancet Respir. Med. 2, 706–716 (2014).

  147. 147

    Raub, T. J. et al. Use of a biophysical-kinetic model to understand the roles of protein binding and membrane partitioning on passive diffusion of highly lipophilic molecules across cellular barriers. J. Drug Target. 1, 269–286 (1993).

  148. 148

    Shakur, H. et al. The BRAIN TRIAL: a randomised, placebo controlled trial of a bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury. Trials 10, 109 (2009).

  149. 149

    Heard, S. O. et al. Effect of prophylactic administration of recombinant human granulocyte colony-stimulating factor (filgrastim) on the frequency of nosocomial infections in patients with acute traumatic brain injury or cerebral hemorrhage. The Filgrastim Study Group. Crit. Care Med. 26, 748–754 (1998).

  150. 150

    Casha, S. et al. Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. Brain 135, 1224–1236 (2012).

  151. 151

    Hanlon, L. A., Huh, J. W. & Raghupathi, R. Minocycline transiently reduces microglia/macrophage activation but exacerbates cognitive deficits following repetitive traumatic brain injury in the neonatal rat. J. Neuropathol. Exp. Neurol. 75, 214–226 (2016).

  152. 152

    Satchell, M. A. et al. Cytochrome c, a biomarker of apoptosis, is increased in cerebrospinal fluid from infants with inflicted brain injury from child abuse. J. Cereb. Blood Flow Metab. 25, 919–927 (2005).

  153. 153

    Rosomoff, H. L. Protective effects of hypothermia against pathological processes of the nervous system. Ann. NY Acad. Sci. 80, 475–486 (1959).

  154. 154

    Marion, D. W. et al. Treatment of traumatic brain injury with moderate hypothermia. N. Engl. J. Med. 336, 540–546 (1997).

  155. 155

    Andrews, P. J. et al. Hypothermia for intracranial hypertension after traumatic brain injury. N. Engl. J. Med. 373, 2403–2412 (2015).

  156. 156

    Clifton, G. L. et al. Very early hypothermia induction in patients with severe brain injury (the National Acute Brain Injury Study: Hypothermia II): a randomised trial. Lancet Neurol. 10, 131–139 (2011).

  157. 157

    Adelson, P. D. et al. Comparison of hypothermia and normothermia after severe traumatic brain injury in children (Cool Kids): a phase 3, randomised controlled trial. Lancet Neurol. 12, 546–553 (2013).

  158. 158

    Deutsch, E. R. et al. Progesterone's role in neuroprotection, a review of the evidence. Brain Res. 1530, 82–105 (2013).

  159. 159

    Wright, D. W. et al. Very early administration of progesterone for acute traumatic brain injury. N. Engl. J. Med. 371, 2457–2466 (2014).

  160. 160

    Skolnick, B. E. et al. A clinical trial of progesterone for severe traumatic brain injury. N. Engl. J. Med. 371, 2467–2476 (2014).

  161. 161

    Diamond, M. L. et al. IL-1β associations with posttraumatic epilepsy development: a genetics and biomarker cohort study. Epilepsia 56, 991–1001 (2015).

  162. 162

    Gentleman, S. M. et al. Long-term intracerebral inflammatory response after traumatic brain injury. Forensic Sci. Int. 146, 97–104 (2004).

  163. 163

    Johnson, V. E. et al. Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain 136, 28–42 (2013).

  164. 164

    Ramlackhansingh, A. F. et al. Inflammation after trauma: microglial activation and traumatic brain injury. Ann. Neurol. 70, 374–383 (2011).

  165. 165

    Smith, D. H., Johnson, V. E. & Stewart, W. Chronic neuropathologies of single and repetitive TBI: substrates of dementia? Nat. Rev. Neurol. 9, 211–221 (2013).

  166. 166

    Smith, C. et al. The neuroinflammatory response in humans after traumatic brain injury. Neuropathol. Appl. Neurobiol. 39, 654–666 (2013).

  167. 167

    Coughlin, J. M. et al. Neuroinflammation and brain atrophy in former NFL players: an in vivo multimodal imaging pilot study. Neurobiol. Dis. 74, 58–65 (2015).

  168. 168

    Juengst, S. B., Kumar, R. G., Arenth, P. M. & Wagner, A. K. Exploratory associations with tumor necrosis factor-alpha, disinhibition and suicidal endorsement after traumatic brain injury. Brain Behav. Immun. 41, 134–143 (2014).

  169. 169

    Nagamoto-Combs, K., McNeal, D. W., Morecraft, R. J. & Combs, C. K. Prolonged microgliosis in the rhesus monkey central nervous system after traumatic brain injury. J. Neurotrauma 24, 1719–1742 (2007).

  170. 170

    Mouzon, B. C. et al. Chronic neuropathological and neurobehavioral changes in a repetitive mild traumatic brain injury model. Ann. Neurol. 75, 241–254 (2014).

  171. 171

    Loane, D. J. et al. Novel mGluR5 positive allosteric modulator improves functional recovery, attenuates neurodegeneration, and alters microglial polarization after experimental traumatic brain injury. Neurotherapeutics 11, 857–869 (2014).

  172. 172

    Holmin, S. & Mathiesen, T. Long-term intracerebral inflammatory response after experimental focal brain injury in rat. Neuroreport 10, 1889–1891 (1999).

  173. 173

    Acosta, S. A. et al. Long-term upregulation of inflammation and suppression of cell proliferation in the brain of adult rats exposed to traumatic brain injury using the controlled cortical impact model. PLoS ONE 8, e53376 (2013).

  174. 174

    Shitaka, Y. et al. Repetitive closed-skull traumatic brain injury in mice causes persistent multifocal axonal injury and microglial reactivity. J. Neuropathol. Exp. Neurol. 70, 551–567 (2011).

  175. 175

    Petraglia, A. L. et al. The spectrum of neurobehavioral sequelae after repetitive mild traumatic brain injury: a novel mouse model of chronic traumatic encephalopathy. J. Neurotrauma 31, 1211–1224 (2014).

  176. 176

    Petraglia, A. L. et al. The pathophysiology underlying repetitive mild traumatic brain injury in a novel mouse model of chronic traumatic encephalopathy. Surg. Neurol. Int. 5, 184 (2014).

  177. 177

    Winston, C. N. et al. Dendritic spine loss and chronic white matter inflammation in a mouse model of highly repetitive head trauma. Am. J. Pathol. 186, 552–567 (2016).

  178. 178

    Byrnes, K. R. et al. Metabotropic glutamate receptor 5 activation inhibits microglial associated inflammation and neurotoxicity. Glia 57, 550–560 (2009).

  179. 179

    Loane, D. J., Stoica, B. A., Byrnes, K. R., Jeong, W. & Faden, A. I. Activation of mGluR5 and inhibition of NADPH oxidase improves functional recovery after traumatic brain injury. J. Neurotrauma 30, 403–412 (2013).

  180. 180

    Byrnes, K. R., Loane, D. J., Stoica, B. A., Zhang, J. & Faden, A. I. Delayed mGluR5 activation limits neuroinflammation and neurodegeneration after traumatic brain injury. J. Neuroinflammation 9, 43 (2012).

  181. 181

    Rodgers, K. M. et al. Reversal of established traumatic brain injury-induced, anxiety-like behavior in rats after delayed, post-injury neuroimmune suppression. J. Neurotrauma 31, 487–497 (2014).

  182. 182

    McKee, A. C. et al. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J. Neuropathol. Exp. Neurol. 68, 709–735 (2009).

  183. 183

    McKee, A. C. et al. The spectrum of disease in chronic traumatic encephalopathy. Brain 136, 43–64 (2013).

  184. 184

    Gardner, R. C. et al. Dementia risk after traumatic brain injury versus nonbrain trauma: the role of age and severity. JAMA Neurol. 71, 1490–1497 (2014).

  185. 185

    Heneka, M. T. et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 14, 388–405 (2015).

  186. 186

    Perry, V. H., Nicoll, J. A. & Holmes, C. Microglia in neurodegenerative disease. Nat. Rev. Neurol. 6, 193–201 (2010).

  187. 187

    McKee, A. C. et al. TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J. Neuropathol. Exp. Neurol. 69, 918–929 (2010).

  188. 188

    Saing, T. et al. Frontal cortex neuropathology in dementia pugilistica. J. Neurotrauma 29, 1054–1070 (2012).

  189. 189

    Cherry, J. D. et al. Microglial neuroinflammation contributes to tau accumulation in chronic traumatic encephalopathy. Acta Neuropathol. Commun. 4, 112 (2016).

  190. 190

    Coughlin, J. M. et al. Imaging of glial cell activation and white matter integrity in brains of active and recently retired National Football League players. JAMA Neurol. 74, 67–74 (2016).

  191. 191

    Webster, K. M. et al. Progesterone treatment reduces neuroinflammation, oxidative stress and brain damage and improves long-term outcomes in a rat model of repeated mild traumatic brain injury. J. Neuroinflammation 12, 238 (2015).

  192. 192

    Hong, Y. T. et al. Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury. JAMA Neurol. 71, 23–31 (2014).

  193. 193

    Barrio, J. R. et al. In vivo characterization of chronic traumatic encephalopathy using [F-18]FDDNP PET brain imaging. Proc. Natl Acad. Sci. USA 112, E2039–E2047 (2015).

  194. 194

    Kumar, R. G., Rubin, J. E., Berger, R. P., Kochanek, P. M. & Wagner, A. K. Principal components derived from CSF inflammatory profiles predict outcome in survivors after severe traumatic brain injury. Brain Behav. Immun. 53, 183–193 (2013).

  195. 195

    Junger, W. G. et al. Prehospital hypertonic saline resuscitation attenuates the activation and promotes apoptosis of neutrophils in patients with severe traumatic brain injury. Shock 40, 366–374 (2013).

  196. 196

    Pagowska-Klimek, I., Lewkowicz, P., Banasik, M., Krajewski, W. & Tchorzewski, H. Isolated head injury in children affects the neutrophil function and lymphocyte count. J. Trauma 63, 179–186 (2007).

  197. 197

    Hazeldine, J., Lord, J. M. & Belli, A. Traumatic brain injury and peripheral immune suppression: primer and prospectus. Front. Neurol. 6, 235 (2015). Excellent review of systemic immune suppression after traumatic brain injury, including future directions for research.

  198. 198

    Hayakata, T. et al. Changes in CSF S100B and cytokine concentrations in early-phase severe traumatic brain injury. Shock 22, 102–107 (2004).

  199. 199

    Maier, B. et al. Delayed elevation of soluble tumor necrosis factor receptors p75 and p55 in cerebrospinal fluid and plasma after traumatic brain injury. Shock 26, 122–127 (2006).

  200. 200

    Ross, S. A., Halliday, M. I., Campbell, G. C., Byrnes, D. P. & Rowlands, B. J. The presence of tumour necrosis factor in CSF and plasma after severe head injury. Br. J. Neurosurg. 8, 419–425 (1994).

  201. 201

    Yan, E. B. et al. Post-traumatic hypoxia is associated with prolonged cerebral cytokine production, higher serum biomarker levels, and poor outcome in patients with severe traumatic brain injury. J. Neurotrauma 31, 618–629 (2014).

  202. 202

    Waters, R. J. et al. Cytokine gene polymorphisms and outcome after traumatic brain injury. J. Neurotrauma 30, 1710–1716 (2013).

  203. 203

    Helmy, A., Carpenter, K. L., Menon, D. K., Pickard, J. D. & Hutchinson, P. J. The cytokine response to human traumatic brain injury: temporal profiles and evidence for cerebral parenchymal production. J. Cereb. Blood Flow Metab. 31, 658–670 (2011).

  204. 204

    Buttram, S. D. et al. Multiplex assessment of cytokine and chemokine levels in cerebrospinal fluid following severe pediatric traumatic brain injury: effects of moderate hypothermia. J. Neurotrauma 24, 1707–1717 (2007).

  205. 205

    Chiaretti, A. et al. Interleukin 1β and interleukin 6 relationship with paediatric head trauma severity and outcome. Childs Nerv. Syst. 21, 185–193 (2005).

  206. 206

    Hadjigeorgiou, G. M. et al. IL-1RN and IL-1B gene polymorphisms and cerebral hemorrhagic events after traumatic brain injury. Neurology 65, 1077–1082 (2005).

  207. 207

    Helmy, A., Antoniades, C. A., Guilfoyle, M. R., Carpenter, K. L. & Hutchinson, P. J. Principal component analysis of the cytokine and chemokine response to human traumatic brain injury. PLoS ONE 7, e39677 (2012).

  208. 208

    Mellergard, P., Aneman, O., Sjogren, F., Saberg, C. & Hillman, J. Differences in cerebral extracellular response of interleukin-1β, interleukin-6, and interleukin-10 after subarachnoid hemorrhage or severe head trauma in humans. Neurosurgery 68, 12–19 (2011).

  209. 209

    Perez-Barcena, J. et al. Lack of correlation among intracerebral cytokines, intracranial pressure, and brain tissue oxygenation in patients with traumatic brain injury and diffuse lesions. Crit. Care Med. 39, 533–540 (2011).

  210. 210

    Hutchinson, P. J. et al. Inflammation in human brain injury: intracerebral concentrations of IL-1α, IL-1β, and their endogenous inhibitor IL-1ra. J. Neurotrauma 24, 1545–1557 (2007).

  211. 211

    Bell, M. J. et al. Interleukin-6 and interleukin-10 in cerebrospinal fluid after severe traumatic brain injury in children. J. Neurotrauma 14, 451–457 (1997).

  212. 212

    Kossmann, T., Hans, V., Imhof, H. G., Trentz, O. & Morganti-Kossmann, M. C. Interleukin-6 released in human cerebrospinal fluid following traumatic brain injury may trigger nerve growth factor production in astrocytes. Brain Res. 713, 143–152 (1996).

  213. 213

    Kossmann, T. et al. Intrathecal and serum interleukin-6 and the acute-phase response in patients with severe traumatic brain injuries. Shock 4, 311–317 (1995).

  214. 214

    Maier, B. et al. Differential release of interleukines 6, 8, and 10 in cerebrospinal fluid and plasma after traumatic brain injury. Shock 15, 421–426 (2001).

  215. 215

    Shore, P. M. et al. Continuous versus intermittent cerebrospinal fluid drainage after severe traumatic brain injury in children: effect on biochemical markers. J. Neurotrauma 21, 1113–1122 (2004).

  216. 216

    Singhal, A. et al. Association between cerebrospinal fluid interleukin-6 concentrations and outcome after severe human traumatic brain injury. J. Neurotrauma 19, 929–937 (2002).

  217. 217

    Winter, C. D., Pringle, A. K., Clough, G. F. & Church, M. K. Raised parenchymal interleukin-6 levels correlate with improved outcome after traumatic brain injury. Brain 127, 315–320 (2004).

  218. 218

    Kirchhoff, C. et al. Cerebrospinal IL-10 concentration is elevated in non-survivors as compared to survivors after severe traumatic brain injury. Eur. J. Med. Res. 13, 464–468 (2008).

  219. 219

    Yan, E. B., Hellewell, S. C., Bellander, B. M., Agyapomaa, D. A. & Morganti-Kossmann, M. C. Post-traumatic hypoxia exacerbates neurological deficit, neuroinflammation and cerebral metabolism in rats with diffuse traumatic brain injury. J. Neuroinflammation 8, 147 (2011).

  220. 220

    Morganti-Kossmann, M. C. et al. TGF-β is elevated in the CSF of patients with severe traumatic brain injuries and parallels blood–brain barrier function. J. Neurotrauma 16, 617–628 (1999).

  221. 221

    Semple, B. D., Bye, N., Rancan, M., Ziebell, J. M. & Morganti-Kossmann, M. C. Role of CCL2 (MCP-1) in traumatic brain injury (TBI): evidence from severe TBI patients and CCL2−/− mice. J. Cereb. Blood Flow Metab. 30, 769–782 (2010).

  222. 222

    Stefini, R. et al. Chemokine detection in the cerebral tissue of patients with posttraumatic brain contusions. J. Neurosurgery 108, 958–962 (2008).

  223. 223

    Whalen, M. J. et al. Interleukin-8 is increased in cerebrospinal fluid of children with severe head injury. Crit. Care Med. 28, 929–934 (2000).

  224. 224

    Engel, S. et al. Dynamics of microglial activation after human traumatic brain injury are revealed by delayed expression of macrophage-related proteins MRP8 and MRP14. Acta Neuropathol. 100, 313–322 (2000).

  225. 225

    Bonneh-Barkay, D. et al. YKL-40 expression in traumatic brain injury: an initial analysis. J. Neurotrauma 27, 1215–1223 (2010).

  226. 226

    Zhang, Z. et al. Human traumatic brain injury induces autoantibody response against glial fibrillary acidic protein and its breakdown products. PLoS ONE 9, e92698 (2014).

  227. 227

    Wagner, A. K. et al. Adenosine A1 receptor gene variants associated with post-traumatic seizures after severe TBI. Epilepsy Res. 90, 259–272 (2010).

  228. 228

    Clark, R. S. et al. Cerebrospinal fluid adenosine concentration and uncoupling of cerebral blood flow and oxidative metabolism after severe head injury in humans. Neurosurgery 41, 1284–1292 (1997).

  229. 229

    Bell, M. J., Kochanek, P. M. & Jackson, E. K. Interstitial adenosine, inosine, and hypoxanthine are increased after experimental traumatic brain injury in the rat. J. Neurotrauma 15, 163–170 (1998).

  230. 230

    Kossmann, T., Stahel, P. F., Morganti-Kossmann, M. C., Jones, J. L. & Barnum, S. R. Elevated levels of the complement components C3 and factor B in ventricular cerebrospinal fluid of patients with traumatic brain injury. J. Neuroimmunol. 73, 63–69 (1997).

  231. 231

    Baker, A. J., Moulton, R. J., MacMillan, V. H. & Shedden, P. M. Excitatory amino acids in cerebrospinal fluid following traumatic brain injury in humans. J. Neurosurg. 79, 369–372 (1993).

  232. 232

    Bullock, R. et al. Factors affecting excitatory amino acid release following severe human head injury. J. Neurosurg. 89, 507–518 (1998).

  233. 233

    Chamoun, R., Suki, D., Gopinath, S. P., Goodman, J. C. & Robertson, C. Role of extracellular glutamate measured by cerebral microdialysis in severe traumatic brain injury. J. Neurosurg. 113, 564–570 (2010).

  234. 234

    Gao, T. L. et al. Expression of HMGB1 and RAGE in rat and human brains after traumatic brain injury. J. Trauma Acute Care Surg. 72, 643–649 (2012).

  235. 235

    Adamczak, S. et al. Inflammasome proteins in cerebrospinal fluid of brain-injured patients as biomarkers of functional outcome: clinical article. J. Neurosurg. 117, 1119–1125 (2012).

  236. 236

    Clark, R. S. et al. Increases in Bcl-2 and cleavage of caspase-1 and caspase-3 in human brain after head injury. FASEB J. 13, 813–821 (1999).

  237. 237

    Mazzeo, A. T. et al. Severe human traumatic brain injury, but not cyclosporin a treatment, depresses activated T lymphocytes early after injury. J. Neurotrauma 23, 962–975 (2006).

  238. 238

    Maas, A. I. et al. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol. 5, 38–45 (2006).

  239. 239

    Nichol, A. et al. Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind randomised controlled trial. Lancet 386, 2499–2506 (2015).

  240. 240

    Robertson, C. S. et al. Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: a randomized clinical trial. JAMA 312, 36–47 (2014).

  241. 241

    Bulger, E. M. et al. Out-of-hospital hypertonic resuscitation following severe traumatic brain injury: a randomized controlled trial. JAMA 304, 1455–1464 (2010).

  242. 242

    Adelson, P. D. et al. Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents. Chapter 11. Use of hyperosmolar therapy in the management of severe pediatric traumatic brain injury. Pediatr. Crit. Care Med. 4, S40–S44 (2003).

  243. 243

    Helmy, A. et al. Recombinant human interleukin-1 receptor antagonist in severe traumatic brain injury: a phase II randomized control trial. J. Cereb. Blood Flow Metab. 34, 845–851 (2014).

  244. 244

    Helmy, A. et al. Recombinant human interleukin-1 receptor antagonist promotes M1 microglia biased cytokines and chemokines following human traumatic brain injury. J. Cereb. Blood Flow Metab. 36, 1434–1448 (2016).

  245. 245

    Tan, M., Zhu, J. C., Du, J., Zhang, L. M. & Yin, H. H. Effects of probiotics on serum levels of Th1/Th2 cytokine and clinical outcomes in severe traumatic brain-injured patients: a prospective randomized pilot study. Crit. Care 15, R290 (2011).

  246. 246

    Tapia-Perez, J. et al. Effect of rosuvastatin on amnesia and disorientation after traumatic brain injury (NCT003229758). J. Neurotrauma 25, 1011–1017 (2008).

  247. 247

    Sanchez-Aguilar, M. et al. Effect of rosuvastatin on cytokines after traumatic head injury. J. Neurosurg. 118, 669–675 (2013).

Download references

Acknowledgements

The authors acknowledge the following funding sources: NIH grants T32 HD40686 (D.W.S.) and R01 NS082308 (D.J.L.); National Institute of Child Health and Human Development grants R01 NS087978 (P.M.K.), NS061817 and NS076511 (H.B.); National Institute of Allergy and Infectious Diseases grant R01 AI110822-01 (M.J.M.); Department of Defense Grants W81XWH-10-1-0623 and W81XWH-14-2-0018 (P.M.K.); NIA Claude D. Pepper Older Americans Independence Center grant P30-AG028747 (D.J.L.); and Children's Hospital of Pittsburgh — Children's Trust (D.W.S.).

Author information

The authors contributed equally to all aspects of the manuscript.

Correspondence to Patrick M. Kochanek.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Glossary

Chronic traumatic encephalopathy

A progressive neurodegenerative disease associated with head trauma and characterized histologically by formation of neurofibrillary tangles, accumulation of phosphorylated TAR DNA-binding protein 43 (TDP-43) accumulation, and deposition of amyloid-β.

Damage-associated molecular patterns

Host-derived molecules that trigger and/or exacarbate the inflammatory response. Prominent examples include DNA and RNA, high mobility group protein B1 (HMGB1), S100 proteins, ATP, uric acid, lysophospholipids, and lipid peroxidation-derived carbonyl adducts of proteins.

CD11d/CD18 integrin

A pattern recognition receptor that is located on the surface of neutrophils and monocytes and is functionally important in recognition of complement, as well as cell–cell interactions and cellular adhesion.

Chemokine gradients

Concentration gradients of chemotactic cytokines with the ability to influence inflammatory cell migration and function. For example, C–C motif chemokine 2 (CCL2), a chemokine for monocytes, macrophages and microglia, and its receptor CCR2 interact to recruit these immune cells to injured tissue after traumatic brain injury.

Autoimmune T cells

Also called autoreactive T cells, these T lymphocytes react to self antigens and may cause autoimmune disease, but are also critical for normal brain function and repair.

TH17 cells

A subset of effector T-helper cells that produce IL-17 and other proinflammatory cytokines.

Glymphatic system

Astrocyte-regulated convective bulk flow of the cerebrospinal fluid from the paravascular space through interstitial fluid in an arterial–venous direction.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Simon, D., McGeachy, M., Bayır, H. et al. The far-reaching scope of neuroinflammation after traumatic brain injury. Nat Rev Neurol 13, 171–191 (2017) doi:10.1038/nrneurol.2017.13

Download citation

Further reading